Fifth Third Bancorp Exelixis, Inc. Transaction History

Fifth Third Bancorp

$27.1 Billion
Q4 2024

A detailed history of Fifth Third Bancorp transactions in Exelixis, Inc. stock. As of the latest transaction made, Fifth Third Bancorp holds 3,231 shares of EXEL stock, worth $124,651. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,231

Previous 2,782 16.14%

Holding current value

$124,651

Previous $72,000 48.61%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Jan 21, 2025	BUY	$25.39 - $36.46 $11,400 - $16,370	449 Added 16.14%	3,231 $107,000
Q3 2024 Oct 17, 2024	BUY	$21.96 - $27.6 $12,451 - $15,649	567 Added 25.6%	2,782 $72,000
Q2 2024 Jul 22, 2024	BUY	$20.34 - $23.73 $5,634 - $6,573	277 Added 14.29%	2,215 $49,000
Q1 2024 Apr 23, 2024	BUY	$20.17 - $23.93 $242 - $287	12 Added 0.62%	1,938 $45,000
Q4 2023 Jan 19, 2024	SELL	$19.25 - $24.13 $847 - $1,061	-44 Reduced 2.23%	1,926 $46,000
Q3 2023 Oct 31, 2023	BUY	$19.04 - $22.74 $11,500 - $13,734	604 Added 44.22%	1,970 $43,000
Q2 2023 Jul 25, 2023	BUY	$18.17 - $20.48 $12,464 - $14,049	686 Added 100.88%	1,366 $26,000
Q1 2023 Apr 24, 2023	BUY	$16.3 - $19.41 $6,340 - $7,550	389 Added 133.68%	680 $13,000
Q4 2022 Jan 25, 2023	SELL	$14.96 - $17.39 $11,190 - $13,007	-748 Reduced 71.99%	291 $0
Q3 2022 Oct 25, 2022	SELL	$15.68 - $22.27 $3,747 - $5,322	-239 Reduced 18.7%	1,039 $16,000
Q2 2022 Aug 04, 2022	BUY	$17.44 - $23.16 $5,528 - $7,341	317 Added 32.99%	1,278 $27,000
Q1 2022 Apr 19, 2022	BUY	$17.03 - $22.67 $11,648 - $15,506	684 Added 246.93%	961 $22,000
Q4 2021 Feb 01, 2022	SELL	$15.84 - $21.88 $7,761 - $10,721	-490 Reduced 63.89%	277 $5,000
Q3 2021 Oct 15, 2021	BUY	$16.3 - $21.14 $5,427 - $7,039	333 Added 76.73%	767 $16,000
Q2 2021 Aug 06, 2021	SELL	$17.95 - $25.56 $1,364 - $1,942	-76 Reduced 14.9%	434 $8,000
Q1 2021 May 07, 2021	BUY	$20.53 - $25.22 $3,798 - $4,665	185 Added 56.92%	510 $12,000
Q4 2020 Feb 16, 2021	SELL	$18.39 - $24.8 $4,781 - $6,448	-260 Reduced 44.44%	325 $7,000
Q3 2020 Nov 09, 2020	BUY	$20.67 - $26.94 $12,091 - $15,759	585 New	585 $14,000
Q2 2020 Aug 05, 2020	SELL	$16.46 - $27.42 $3,292 - $5,484	-200 Closed	0 $0
Q1 2020 May 05, 2020	SELL	$14.46 - $21.8 $2,009 - $3,030	-139 Reduced 41.0%	200 $3,000
Q4 2019 Feb 14, 2020	SELL	$15.15 - $18.89 $27,270 - $34,002	-1,800 Reduced 84.15%	339 $6,000
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $34,281 - $43,918	1,939 Added 969.5%	2,139 $38,000
Q1 2019 May 14, 2019	BUY	$19.6 - $24.76 $3,920 - $4,952	200 New	200 $5,000

Others Institutions Holding EXEL

# of Institutions

566

Shares Held

251M

Call Options Held

1.45M

Put Options Held

1.13M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $12.4B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.

Account

Fifth Third Bancorp Exelixis, Inc. Transaction History